Welcome to our dedicated page for Teva Pharmaceutical Industries American Depositary Shares news (Ticker: TEVA), a resource for investors and traders seeking the latest updates and insights on Teva Pharmaceutical Industries American Depositary Shares stock.
Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) is a leading Israeli multinational pharmaceutical company headquartered in Tel Aviv, Israel. As the world's largest generic drug manufacturer, Teva plays a pivotal role in the global healthcare industry. The company derives approximately 50% of its sales from North America, contributing significantly to the total number of generic prescriptions in the United States.
Teva's extensive portfolio includes not only generic drugs but also active pharmaceutical ingredients (APIs) and proprietary pharmaceuticals. The company's operations are categorized into three main therapeutic areas:
- Central Nervous System (CNS): Featuring notable products such as Copaxone, Ajovy, and Austedo, Teva addresses critical CNS disorders with innovative treatments.
- Respiratory: Products like Qvar and ProAir contribute to Teva's robust respiratory medicine lineup, catering to patients with various respiratory conditions.
- Oncology: Teva's oncology portfolio includes groundbreaking medicines such as Truxima, Herzuma, and Bendeka/Treanda, providing essential treatments for cancer patients.
In addition to its pharmaceutical products, Teva is a major player in active pharmaceutical ingredients, offering contract manufacturing services and owning Anda, a U.S.-based distributor of generic and specialty drugs.
Teva's global presence extends beyond North America, with significant operations in Europe, Japan, Russia, and its home country, Israel. The company's strategic partnerships and innovations keep it at the forefront of the pharmaceutical industry. Recent developments include advancements in biosimilars and innovative treatments.
Financially, Teva continues to maintain a strong position, focusing on growth and resilience amidst market challenges. The company is committed to improving patient health worldwide by providing high-quality, affordable medicines.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) announced that their President and CEO, Richard Francis, will deliver a presentation at the Jefferies London Healthcare Conference on November 19, 2024, at 8:30 AM GMT (3:30 AM ET). The presentation will be accessible via live webcast on Teva's Investor Relations website, with an archived version available within 24 hours after the live session concludes.
Teva Pharmaceutical reported strong Q3 2024 results with revenues of $4.3 billion, up 13% year-over-year. Key highlights include AUSTEDO U.S. revenues reaching $435 million (+28%), AJOVY global revenues of $137 million (+21%), and UZEDY U.S. revenues of $35 million. The generics business showed significant growth across all regions. Based on strong performance, Teva raised its 2024 outlook, projecting revenues of $16.1-$16.5 billion, Adjusted EBITDA of $4.7-$5.0 billion, and Non-GAAP EPS of $2.40-$2.50.
Teva Pharmaceuticals announced new interim results from the Phase 4 IMPACT-TD Registry study, revealing key differences in tardive dyskinesia (TD) experiences between patients with psychotic and mood disorders. The study, the largest of its kind, showed that fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%), despite similar AIMS scores.
The study also presented real-world patient experience data with AUSTEDO XR, showing that 87% reported satisfaction with the medication, and 74% reported improvement in their extra movements. The registry highlighted that TD significantly impacts quality of life regardless of underlying mental health conditions.
Teva Pharmaceuticals announced positive data from the Phase 3 SOLARIS trial of TEV-'749, a subcutaneous long-acting injectable for schizophrenia treatment. The trial demonstrated significant improvements in social functioning and quality of life across multiple measures from baseline to week 8. Key findings showed no Post-Injection Delirium/Sedation Syndrome events and met primary endpoints across all dosing groups. The company also presented real-world analyses of UZEDY®, showing high adherence rates (69%) among patients with various social challenges, including those with housing instability and food insecurity. The systemic safety profile was consistent with other approved oral formulations, with no new safety signals identified.
Teva Pharmaceuticals has announced its intention to appeal a European Commission decision regarding its practices related to COPAXONE®, a multiple sclerosis treatment. The company strongly disagrees with the Commission's decision, which it describes as based on extreme and untested legal theories lacking factual support.
The company has been cooperating with the EC since 2019 and states it will vigorously defend its position. Teva emphasizes its commitment to ethical business practices and continued support for MS patients, while noting it is financially prepared to mount its defense.
Alvotech and Teva announced FDA approval of a new presentation of SELARSDI™ (ustekinumab-aekn), expanding its label to include treatment of adults with Crohn's disease and ulcerative colitis. The approval is for a 130 mg/26 mL single-dose vial for intravenous infusion, complementing the previously approved 45 mg/0.5 mL and 90 mg/mL prefilled syringes for subcutaneous injection.
SELARSDI's U.S. launch for all indications is expected in Q1 2025. This approval aligns SELARSDI's label with the reference product Stelara® (ustekinumab). The companies highlighted successful launches of the first biosimilar ustekinumab in Canada, Japan, and Europe. Alvotech developed SELARSDI using the same cell line and process as the reference product.
This approval is part of a broader strategic partnership between Alvotech and Teva, which now includes nine biosimilar products.
Teva Pharmaceutical Industries announced that the U.S. FDA has accepted and the EU EMA has validated applications for TVB-009P, a biosimilar candidate to Prolia® (denosumab). The applications seek approval for all indications of Prolia, including osteoporosis in postmenopausal women. Decisions from both agencies are expected in the second half of 2025.
TVB-009P is Teva's first internally developed biosimilar submitted to the U.S. FDA. The submissions are supported by comprehensive data, including results from a Phase 3 trial and a pharmacokinetics study. Teva, with over 120 years of experience, is a leader in the biosimilar market with 7 approved biosimilars and 16 in the pipeline.
The company aims to expand access to affordable treatment options, particularly for conditions like osteoporosis, which affects about 25% of older women in the U.S. and EU.
Teva Pharmaceuticals and mAbxience have expanded their strategic partnership to include an additional oncology biosimilar candidate. This new global licensing agreement focuses on the development of an anti PD-1 oncology biosimilar, marking their second collaboration since April 2024. The partnership aligns with Teva's Pivot to Growth strategy and enhances its biosimilar portfolio.
Under the agreement, mAbxience will lead the development and production of the biosimilar using its facilities in Spain and Argentina, while Teva will manage regulatory approvals and commercialization in designated markets, including Europe and the United States. This collaboration aims to provide cost-effective, high-quality biosimilar treatments in oncology care, addressing unmet needs and improving global healthcare accessibility.
Teva Pharmaceuticals has launched the first and only generic version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension) in the United States. This medication is used to treat acromegaly and severe diarrhea associated with carcinoid syndrome. The launch demonstrates Teva's expertise in complex generic formulations and supports its goal of maintaining a strong position in the generics market.
Octreotide acetate for injectable suspension is indicated for long-term maintenance therapy in acromegalic patients and for the long-term treatment of severe diarrhea and flushing episodes related to metastatic carcinoid tumors and VIP-secreting tumors. The annual sales of Sandostatin® LAR Depot were $826 million as of July 2024, according to IQVIA data.
Teva Pharmaceutical Industries (NYSE and TASE: TEVA) has announced its plans to release its third quarter 2024 financial results on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following this release, the company will host a conference call and live webcast at 8:00 a.m. ET on the same day.
Interested participants are required to register in advance to obtain a local or toll-free phone number and personal pin for the call. A live webcast will be available on Teva's investor relations website. After the call's conclusion, a replay of the webcast will be accessible within 24 hours on the company's website.
FAQ
What is the current stock price of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?
What is the market cap of Teva Pharmaceutical Industries American Depositary Shares (TEVA)?
What does Teva Pharmaceutical Industries Limited specialize in?
Where is Teva headquartered?
What are some of Teva's key products?
In which regions does Teva operate?
How much of Teva's sales come from North America?
What therapeutic areas does Teva focus on?
What is Anda?
Does Teva offer contract manufacturing services?
What role does Teva play in the U.S. generic prescription market?